The P-III (IMscin001) study evaluating the PK, safety & efficacy of Tecentriq as SC formulation vs IV Tecentriq in 371 patients with prior treated LA or metastatic NSCLC.
The trial met its co-primary EPs & showed non-inferior levels of Tecentriq in the blood over IV infusion in cancer immunotherapy-naïve patients, Tecentriq (SC) decreased the treatment period from 30 to 60min. to 3 to 8min. per inj. The safety profile of the SC formulation was consistent with that of IV Tecentriq
The results will be shared at an upcoming medical meeting & submit to health authorities globally for regulatory approval incl. the US FDA & EMA. Tecentriq is a mAb targeting PD-L1 acts by blocking its interactions with PD-1 & B7.1 receptor
Ref: Roche | Image: Roche
